- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05377320
Patiëntovereenkomst voor besluitvorming bij preventie van cardiovasculaire toxiciteit (PACT): een haalbaarheidsonderzoek
This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
For this feasibility study, the researchers will create the clinical decision aid and test the central hypothesis that this novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists and will favorably impact appropriate medication use and cardiac imaging surveillance. The hypothesis is supported by preliminary data suggesting that an initial and rudimentary version of the clinical aid increases appropriate medication use and imaging follow-up in cardio-oncology patients. Success will be determined by ≥85% of clinic visits using the clinical decision aid resulting in pursuit of medication use and cardiac imaging surveillance patterns commensurate with recommendations specific to cancer survivors, with overall rates the same or higher than the group without the clinical decision aid, as well as overall favorable patient and physician focus group comments and survey responses.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Yee Chung Cheng, MD
- Telefoonnummer: 414-805-4600
- E-mail: ycheng@mcw.edu
Studie Locaties
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Froedtert & the Medical College of Wisconsin
-
Hoofdonderzoeker:
- Yee Chung Chen, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Cancer survivors at intermediate, high, or very high risk for developing cardiovascular disease will pursue a cardio-oncology visit.
Beschrijving
Inclusion Criteria:
- Patients ≥18 years with a history of cancer.
- Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.
- Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.
- Ability to understand a written informed consent form, and willing to sign it prior to study registration.
Exclusion Criteria:
- Patient <18 years.
- Without a personal history of cancer.
- Existing cardiomyopathy diagnosed after cancer diagnosis.
- Documented cognitive impairment.
- Patient or patient representative who is unable and unwilling to sign the informed consent form.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Clinical Decision Aid Group
In this group, physicians will use standard care plus the clinical decision aid. |
The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24. |
|
Control Group
In this group, physicians will use standard care only. |
Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Medication use
Tijdsspanne: Week 0
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 0
|
|
Medication use
Tijdsspanne: Week 12
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 12
|
|
Medication use
Tijdsspanne: Week 24
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 24
|
|
Imaging surveillance
Tijdsspanne: Week 0
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 0
|
|
Imaging surveillance
Tijdsspanne: Week 12
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 12
|
|
Imaging surveillance
Tijdsspanne: Week 24
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 24
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Yee Chung Cheng, MD, Medical College of Wisconsin
Publicaties en nuttige links
Algemene publicaties
- Brown SA, Chung BY, Doshi K, Hamid A, Pederson E, Maddula R, Hanna A, Choudhuri I, Sparapani R, Bagheri Mohamadi Pour M, Zhang J, Kothari AN, Collier P, Caraballo P, Noseworthy P, Arruda-Olson A; Cardio-Oncology Artificial Intelligence Informatics and Precision Equity (CAIPE) Research Team Investigators. Patient similarity and other artificial intelligence machine learning algorithms in clinical decision aid for shared decision-making in the Prevention of Cardiovascular Toxicity (PACT): a feasibility trial design. Cardiooncology. 2023 Jan 23;9(1):7. doi: 10.1186/s40959-022-00151-0.
- Brown SA, Hamid A, Pederson E, Bs AH, Maddula R, Goodman R, Lamberg M, Caraballo P, Noseworthy P, Lukan O, Echefu G, Berman G, Choudhuri I; Cardio-Oncology Artificial Intelligence Informatics & Precision Equity (CAIPE) and Patient Similarity Algorithms in the Prevention of Cardiovascular Toxicity (PACT) Research Team Investigators. Simplified rules-based tool to facilitate the application of up-to-date management recommendations in cardio-oncology. Cardiooncology. 2023 Oct 27;9(1):37. doi: 10.1186/s40959-023-00179-w.
- Brown SA, Fang MZ, Sparapani R, Zhou Y, Osinski K, Taylor B, Yu D, Blessing J, Shah R, Collier P, BagheriMohamadiPour M, Zhang J, Kothari A, Echefu G, Rickards J, Otto C, Sanchez Z, Olson J, Arruda-Olson A, Cheng YC, Cheng F; Cardio-Oncology Artificial Intelligence Informatics and Precision Equity, and Patient Similarity Algorithms in the Prevention of Cardiovascular Toxicity Research Team Investigators. PrevCardioOncAI: Machine Learning Algorithms for Predicting Cardiovascular Disease in Cancer Survivors. J Am Heart Assoc. 2025 Dec 16;14(24):e030363. doi: 10.1161/JAHA.123.030363. Epub 2025 Dec 11.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Vaatziekten
- Hart-en vaatziekten
- Wonden en verwondingen
- Pathologische processen
- Hartziekten
- Metabole ziekten
- Glucosemetabolismestoornissen
- Chemisch veroorzaakte aandoeningen
- Geneesmiddelgerelateerde bijwerkingen en bijwerkingen
- Stralingsverwondingen
- Atherosclerose
- Arteriosclerose
- Arteriële occlusieve ziekten
- Perifere vaataandoeningen
- Hart-en vaatziekte
- Myocardiale ischemie
- Pathologische aandoeningen, tekenen en symptomen
- Voedings- en stofwisselingsziekten
- Neoplasmata
- Hartfalen
- Hypertensie
- Ischemie
- Suikerziekte
- Cardiomyopathieën
- Perifere arteriële ziekte
- Coronaire hartziekte
- Cardiotoxiciteit
- Health Services Administration
- Kwaliteit, toegang en evaluatie van de gezondheidszorg
- Kwaliteit van de gezondheidszorg
- Kwaliteitsindicatoren, gezondheidszorg
- Zorgstandaard
Andere studie-ID-nummers
- PRO00039290
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .